Cargando…

Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients

Identifying modifiable risk factors of peritoneal dialysis (PD)-related peritonitis is of clinical importance in patient care. Mineral bone disease (MBD) has been associated with mortality and morbidity in end-stage kidney disease (ESKD) patients. However, its influence on PD related peritonitis due...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Chia-Te, Zheng, Cai-Mei, Lin, Yen-Chung, Wu, Mei-Yi, Lin, Yuh-Feng, Hsu, Yung-Ho, Hsu, Chih-Cheng, Wu, Mai-Szu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806837/
https://www.ncbi.nlm.nih.gov/pubmed/33441921
http://dx.doi.org/10.1038/s41598-020-80938-2
_version_ 1783636611639017472
author Liao, Chia-Te
Zheng, Cai-Mei
Lin, Yen-Chung
Wu, Mei-Yi
Lin, Yuh-Feng
Hsu, Yung-Ho
Hsu, Chih-Cheng
Wu, Mai-Szu
author_facet Liao, Chia-Te
Zheng, Cai-Mei
Lin, Yen-Chung
Wu, Mei-Yi
Lin, Yuh-Feng
Hsu, Yung-Ho
Hsu, Chih-Cheng
Wu, Mai-Szu
author_sort Liao, Chia-Te
collection PubMed
description Identifying modifiable risk factors of peritoneal dialysis (PD)-related peritonitis is of clinical importance in patient care. Mineral bone disease (MBD) has been associated with mortality and morbidity in end-stage kidney disease (ESKD) patients. However, its influence on PD related peritonitis due to altered host immunity remains elusive. This study investigated whether abnormal biomarkers of MBD are associated with the development of peritonitis in patients undergoing maintenance PD. We conducted a retrospective observational cohort study, analysing data derived from a nationwide dialysis registry database in Taiwan, from 2005 to 2012. A total of 5750 ESKD patients commencing PD therapy during this period were enrolled and followed up to 60 months or by the end of the study period. The patients were stratified based on their baseline serum parathyroid hormone (PTH) levels, calcium (Ca) levels or phosphorus (P) levels, respectively or in combinations. The primary outcome was the occurrence of first episode of peritonitis, and patient outcomes such as deaths, transfer to haemodialysis or receiving renal transplantation were censored. Peritonitis-free survival and the influence of PTH, Ca, P (individual or in combination) on the peritonitis occurrence were analysed. A total of 5750 PD patients was enrolled. Of them, 1611 patients experienced their first episode of peritonitis during the study period. Patients with low PTH, high Ca or low P levels, respectively or in combination, had the lowest peritonitis-free survival. After adjusting for age, sex and serum albumin levels, we found that the combinations of low PTH levels with either high Ca levels or low/normal P levels were significant risk factors of developing peritonitis. Abnormal mineral bone metabolism in maintenance PD patients with low serum PTH levels, in combination with either high Ca levels or low/normal P levels, could be novel risk factors of PD-related peritonitis.
format Online
Article
Text
id pubmed-7806837
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78068372021-01-14 Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients Liao, Chia-Te Zheng, Cai-Mei Lin, Yen-Chung Wu, Mei-Yi Lin, Yuh-Feng Hsu, Yung-Ho Hsu, Chih-Cheng Wu, Mai-Szu Sci Rep Article Identifying modifiable risk factors of peritoneal dialysis (PD)-related peritonitis is of clinical importance in patient care. Mineral bone disease (MBD) has been associated with mortality and morbidity in end-stage kidney disease (ESKD) patients. However, its influence on PD related peritonitis due to altered host immunity remains elusive. This study investigated whether abnormal biomarkers of MBD are associated with the development of peritonitis in patients undergoing maintenance PD. We conducted a retrospective observational cohort study, analysing data derived from a nationwide dialysis registry database in Taiwan, from 2005 to 2012. A total of 5750 ESKD patients commencing PD therapy during this period were enrolled and followed up to 60 months or by the end of the study period. The patients were stratified based on their baseline serum parathyroid hormone (PTH) levels, calcium (Ca) levels or phosphorus (P) levels, respectively or in combinations. The primary outcome was the occurrence of first episode of peritonitis, and patient outcomes such as deaths, transfer to haemodialysis or receiving renal transplantation were censored. Peritonitis-free survival and the influence of PTH, Ca, P (individual or in combination) on the peritonitis occurrence were analysed. A total of 5750 PD patients was enrolled. Of them, 1611 patients experienced their first episode of peritonitis during the study period. Patients with low PTH, high Ca or low P levels, respectively or in combination, had the lowest peritonitis-free survival. After adjusting for age, sex and serum albumin levels, we found that the combinations of low PTH levels with either high Ca levels or low/normal P levels were significant risk factors of developing peritonitis. Abnormal mineral bone metabolism in maintenance PD patients with low serum PTH levels, in combination with either high Ca levels or low/normal P levels, could be novel risk factors of PD-related peritonitis. Nature Publishing Group UK 2021-01-13 /pmc/articles/PMC7806837/ /pubmed/33441921 http://dx.doi.org/10.1038/s41598-020-80938-2 Text en © The Author(s) 2021, corrected publication 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Liao, Chia-Te
Zheng, Cai-Mei
Lin, Yen-Chung
Wu, Mei-Yi
Lin, Yuh-Feng
Hsu, Yung-Ho
Hsu, Chih-Cheng
Wu, Mai-Szu
Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients
title Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients
title_full Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients
title_fullStr Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients
title_full_unstemmed Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients
title_short Aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients
title_sort aberrant serum parathyroid hormone, calcium, and phosphorus as risk factors for peritonitis in peritoneal dialysis patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806837/
https://www.ncbi.nlm.nih.gov/pubmed/33441921
http://dx.doi.org/10.1038/s41598-020-80938-2
work_keys_str_mv AT liaochiate aberrantserumparathyroidhormonecalciumandphosphorusasriskfactorsforperitonitisinperitonealdialysispatients
AT zhengcaimei aberrantserumparathyroidhormonecalciumandphosphorusasriskfactorsforperitonitisinperitonealdialysispatients
AT linyenchung aberrantserumparathyroidhormonecalciumandphosphorusasriskfactorsforperitonitisinperitonealdialysispatients
AT wumeiyi aberrantserumparathyroidhormonecalciumandphosphorusasriskfactorsforperitonitisinperitonealdialysispatients
AT linyuhfeng aberrantserumparathyroidhormonecalciumandphosphorusasriskfactorsforperitonitisinperitonealdialysispatients
AT hsuyungho aberrantserumparathyroidhormonecalciumandphosphorusasriskfactorsforperitonitisinperitonealdialysispatients
AT hsuchihcheng aberrantserumparathyroidhormonecalciumandphosphorusasriskfactorsforperitonitisinperitonealdialysispatients
AT wumaiszu aberrantserumparathyroidhormonecalciumandphosphorusasriskfactorsforperitonitisinperitonealdialysispatients